Show simple item record

dc.contributor.authorGillies, M.
dc.contributor.authorWalton, R.
dc.contributor.authorLiong, J.
dc.contributor.authorArnold, J.
dc.contributor.authorMcAllister, I.
dc.contributor.authorMorlet, Nigel
dc.contributor.authorHunyor, A.
dc.contributor.authorGuymer, R.
dc.contributor.authorKeeffe, J.
dc.contributor.authorEssex, R.
dc.contributor.authorHerrera-Bond, A.
dc.contributor.authorGlastonbury, B.
dc.contributor.authorSimpson, J.
dc.contributor.authorBarthelmes, D.
dc.date.accessioned2017-01-30T15:30:26Z
dc.date.available2017-01-30T15:30:26Z
dc.date.created2015-10-29T04:09:54Z
dc.date.issued2014
dc.identifier.citationGillies, M. and Walton, R. and Liong, J. and Arnold, J. and McAllister, I. and Morlet, N. and Hunyor, A. et al. 2014. Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project. Retina. 34 (1): pp. 188-195.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/46975
dc.identifier.doi10.1097/IAE.0b013e318296b271
dc.description.abstract

Purpose: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. Methods: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. Results: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%. Conclusion: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice. Copyright © 2014 by Ophthalmic Communications Society, Inc.

dc.titleEfficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project
dc.typeJournal Article
dcterms.source.volume34
dcterms.source.number1
dcterms.source.startPage188
dcterms.source.endPage195
dcterms.source.issn0275-004X
dcterms.source.titleRetina
curtin.departmentCentre for Population Health Research
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record